Interpace Diagnostics Group Inc. ( (IDXG) ) has released its Q3 earnings. Here is a breakdown of the information Interpace Diagnostics Group Inc. presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Interpace Biosciences, Inc. is a company specializing in molecular diagnostics, bioinformatics, and pathology services, primarily focusing on cancer risk evaluation through advanced genomic tests. In its latest earnings report for the quarter ended September 30, 2025, Interpace Biosciences reported a net income of $911,000, a decrease from $1.676 million in the same period last year, reflecting challenges in revenue generation. Key financial highlights include a revenue decline to $8.756 million from $12.295 million year-over-year, and a reduction in operating expenses, resulting in an operating income of $1.145 million. The company faced significant impacts from the loss of Medicare coverage for its PancraGEN test, leading to restructuring efforts aimed at cost reduction. Looking forward, Interpace Biosciences plans to navigate its financial challenges through strategic alternatives and cost management, while exploring new funding opportunities to support its operations.